Patents by Inventor Rafiuddin Dr

Rafiuddin Dr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline bortezomib process
    Patent number: 11964993
    Abstract: The present invention relates to a process for the preparation of crystalline Bortezomib of formula (I) and its pharmaceutical acceptable salts thereof. The present invention relates to a process for the preparation of highly pure crystalline Bortezomib (I).
    Type: Grant
    Filed: June 14, 2022
    Date of Patent: April 23, 2024
    Assignee: SHILPA PHARMA LIFESCIENCES LIMITED
    Inventors: Rafiuddin Dr, Ananta Naga Kanaka Durga Reddy Guntaka
  • CRYSTALLINE BORTEZOMIB PROCESS
    Publication number: 20230002418
    Abstract: The present invention relates to a process for the preparation of crystalline Bortezomib of formula (I) and its pharmaceutical acceptable salts thereof. The present invention relates to a process for the preparation of highly pure crystalline Bortezomib (I).
    Type: Application
    Filed: June 14, 2022
    Publication date: January 5, 2023
    Inventors: Rafiuddin Dr, Ananta Naga Kanaka Durga Reddy Guntaka
  • PROCESS FOR THE PREPARTION OF AMIFAMPRIDINE PHOSPHATE
    Publication number: 20220127231
    Abstract: The present invention relates to an improved process for the preparation of substantially pure Amifampridine phosphate The present invention further relates to a substantially pure Amifampridine Phosphate, useful for the preparation of pharmaceutical composition thereof.
    Type: Application
    Filed: September 14, 2021
    Publication date: April 28, 2022
    Applicant: SHILPA MEDICARE LTD
    Inventors: RAFIUDDIN Dr, YUVATEJA BOYINA
  • Process for the preparation of fingolimod and its salts
    Patent number: 9732030
    Abstract: The present invention provides process for preparation of Fingolimod hydrochloride (I). Fingolimod hydrochloride (I) as Form-? obtained by the process of present invention may be useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of autoimmune related disorder including multiple sclerosis.
    Type: Grant
    Filed: January 11, 2014
    Date of Patent: August 15, 2017
    Assignee: SHILPA MEDICARE LIMITED
    Inventors: Vimal Kumar Shrawat, Rafiuddin Dr, Akshaykant Chaturvedi
  • PROCESS FOR PREPARATION OF DIMETHYL-(E)-BUTENEDIOATE
    Publication number: 20160326087
    Abstract: The present invention relates to a process for preparation of dimethyl-(E)-butenedioate(I). The process for preparation of dimethyl-(E)-butenedioate (I), comprises reaction of Fumaric acid with methanol in the presence of C2-C4alkanoyl halideas coupling catalyst.
    Type: Application
    Filed: October 18, 2014
    Publication date: November 10, 2016
    Applicant: SHILPA MEDICARE LIMITED
    Inventors: RAFIUDDIN DR, BHAGAT RAJ PIPAL, RAVINDRA REDDY UMMADI, AKSHAY KANT CHATURVEDI
  • Process for preparing amorphous cabazitaxel
    Patent number: 9403785
    Abstract: The present invention provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), and process for preparation thereof. The present application also provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) having an XRPD pattern as per FIG. 1, and IR spectrum as per FIG. 3 and is useful as an active pharmaceutical in a pharmaceutical composition comprising thereof and has anti-cancer activity.
    Type: Grant
    Filed: December 26, 2012
    Date of Patent: August 2, 2016
    Assignee: SHILPA MEDICARE LIMITED
    Inventors: Vimal Kumar Shrawat, Prashant Purohit, Rafiuddin Dr, Vinod Kumar Singh, Akshay Kant Chaturvedi
  • Process for preparation of 2-chloro--(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms
    Patent number: 9278932
    Abstract: The present invention relates to crystalline 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide (I) designated as Form-SV and process for preparation thereof. The invention further relates to pharmaceutical compositions comprising crystalline Form-SV or non-crystalline form of (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, useful in the treatment of cancer.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: March 8, 2016
    Assignee: SHILPA MEDICARE LIMITED
    Inventors: Rafiuddin Dr, Vinod Kumar Singh, Nagnnath Kokare, Akshaykant Chaturvedi
  • PROCESS FOR PREPARATION OF 2-CHLORO-N-(4-CHLORO-3-PYRIDIN-2-YLPHENYL)-4-METHYLSULFONYLBENZAMIDE SOLID FORMS
    Publication number: 20160060220
    Abstract: The present invention relates to crystalline 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide (I) designated as Form-SV and process for preparation thereof. The invention further relates to pharmaceutical compositions comprising crystalline Form-SV or non-crystalline form of (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, useful in the treatment of cancer.
    Type: Application
    Filed: March 5, 2014
    Publication date: March 3, 2016
    Applicant: SHILPA MEDICARE LIMITED
    Inventors: RAFIUDDIN DR, VINOD KUMAR SINGH, NAGNNATH KOKARE, AKSHAYKANT CHATURVEDI
  • PROCESS FOR THE PREPARATION OF FINGOLIMOD AND ITS SALTS
    Publication number: 20150344409
    Abstract: The present invention provides process for preparation of Fingolimod hydrochloride (I). Fingolimod hydrochloride (I) as Form-? obtained by the process of present invention may be useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of autoimmune related disorder including multiple sclerosis.
    Type: Application
    Filed: January 11, 2014
    Publication date: December 3, 2015
    Applicant: SHILPA MEDICARE LIMITED
    Inventors: VIMAL KUMAR SHRAWAT, RAFIUDDIN DR, AKSHAYKANT CHATURVEDI
  • PROCESS FOR PREPARING AMORPHOUS CABAZITAXEL
    Publication number: 20140336246
    Abstract: The present invention provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), and process for preparation thereof. The present application also provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) having an XRPD pattern as per FIG. 1, and IR spectrum as per FIG. 3 and is useful as an active pharmaceutical in a pharmaceutical composition comprising thereof and has anti-cancer activity.
    Type: Application
    Filed: December 26, 2012
    Publication date: November 13, 2014
    Applicant: SHILPA MEDICARE LIMITED
    Inventors: Vimal Kumar Shrawat, Prashant Purohit, Rafiuddin Dr, Vinod Kumar Singh, Akshaykant Chaturvedi